BRUIN CLL-314 is the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve patients INDIANAPOLIS, July 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: ...
Eilean Therapeutics is a biopharmaceutical company focused on the development of best-in-class and first-in-class small molecule inhibitors that target escape mutations in hematologic malignancies and ...
The drug is the second cardiac myosin inhibitor to get regulatory signoff in the United States, following mavacamten in 2022.
In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. HSK31858 given as 20 mg or 40 mg performed better than ...
MADISON, Wis.--(BUSINESS WIRE)--Research published in Science reveals a new target for non-hormonal male contraception. The protein, a kinase called STK33, has been linked to infertility in male mice ...
Pirtobrutinib met the primary endpoint of response rate non-inferiority, favoring pirtobrutinib with a nominal P-value for superiority < 0.05 Progression-free survival data was immature, but trending ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback